FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “NLS Pharmaceutics Ltd. Surges Amid License Agreement with Novartis Pharma AGs”
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) shot up over 109% in premarket trading after the Company had entered into a License Agreement with Novartis Pharma AG.
The agreement grants NLS all of the available data referred to and included in the original NDA for Sanorex® and includes the right to sublicense or assign the license to third parties, subject to such third parties meeting certain obligations.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company’s lead product candidate, Quilience® is a proprietary controlled release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.
For more information, please visit: NLS Pharmaceutics Ltd.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.